Physician profile
Jerrod Taylor
NPI 1427154327
$11,213.68
in general payments reported to CMS, 2019-2025
42 companies · $3,540 in 2025
The $3,540 reported for 2025 was more than what 85% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2020: $109 · 2021: $180 · 2022: $485 · 2023: $2,602 · 2024: $4,045 · 2025: $3,540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,078 · Education: $4,094 · Travel and Lodging: $1,015.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,077.99 |
| Education | $4,093.99 |
| Travel and Lodging | $1,015.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,552.43 | 2023-2025 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $1,253.07 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Medical Device Business Services, INC. | $743.86 | 2023 | Na |
| Astrazeneca Pharmaceuticals Lp | $593.18 | 2020-2025 | Fasenra, Tezspire, Breztri |
| Actelion Pharmaceuticals US, INC. | $496.66 | 2022-2025 | Uptravi, Opsumit |
| Insmed, INC. | $327.63 | 2019-2025 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $310.07 | 2020-2025 | Ofev, Jascayd |
| Merck Sharp & Dohme LLC | $292.33 | 2019-2025 | Winrevair, Keytruda, Zerbaxa |
| Grifols USA, LLC | $291.28 | 2023-2025 | Prolastin-C Liquid |
| United Therapeutics Corporation | $291.13 | 2023-2025 | Tyvaso, Tyvaso, Orenitram |
| Takeda Pharmaceuticals U.S.A., INC. | $249.01 | 2023-2025 | Glassia |
| Pulmonx Corporation | $135.80 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Mylan Specialty L.P. | $129.81 | 2022-2024 | Yupelri |
| Electromed, INC. | $127.67 | 2019-2025 | Smartvest |
| Genzyme Corporation | $122.64 | 2024-2025 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $119.24 | 2023 | Inspire |
| Ani Pharmaceuticals, INC. | $113.30 | 2023-2025 | Purified Cortrophin Gel |
| Baxter Healthcare | $106.74 | 2023-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Bayer Healthcare Pharmaceuticals INC. | $106.22 | 2019-2023 | |
| Verona Pharma, INC. | $84.51 | 2025 | Ohtuvayre |
| Novartis Pharmaceuticals Corporation | $79.85 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $79.16 | 2021-2024 | Dupixent |
| Mallinckrodt Hospital Products INC. | $69.68 | 2024-2025 | Acthar |
| Amgen INC. | $54.74 | 2025 | Tezspire |
| Viatris Specialty LLC | $43.24 | 2025 | Yupelri |
| La Jolla Pharmaceutical Company | $39.63 | 2025 | Giapreza |
| Lilly USA, LLC | $39.57 | 2025 | Zepbound |
| Jazz Pharmaceuticals INC. | $39.32 | 2019 | |
| Genentech USA, INC. | $33.91 | 2019-2020 | |
| Astellas Pharma US INC | $33.16 | 2025 | Cresemba |
| Philips North America LLC | $30.11 | 2023-2025 | Vest Therapy Und |
| Lungpacer Medical USA INC | $27.21 | 2025 | Aeropace Neurostimulation Console |
| Abbvie INC. | $24.05 | 2024 | |
| Vifor Pharma, INC. | $23.09 | 2025 | Zemaira |
| Janssen Biotech, INC. | $21.67 | 2025 | Tremfya |
| Xeris Pharmaceuticals, INC. | $20.79 | 2025 | Recorlev |
| Alexion Pharmaceuticals, INC. | $20.48 | 2023 | Ultomiris |
| Breas Medical, INC. | $20.47 | 2025 | Vivo 45 Ls |
| Melinta Therapeutics, LLC | $20.20 | 2022 | |
| Pfizer INC. | $19.21 | 2024 | |
| Inogen, INC. | $13.82 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $13.74 | 2024 | Baqsimi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerrod Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.